Cantor Fitzgerald Brokers Reduce Earnings Estimates for ARTV

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of Artiva Biotherapeutics in a research note issued to investors on Tuesday, March 25th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($2.91) per share for the year, down from their previous estimate of ($2.72). Cantor Fitzgerald has a “Overweight” rating and a $20.00 price objective on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share.

Several other research firms have also issued reports on ARTV. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Tuesday. Wedbush restated an “outperform” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $20.40.

Artiva Biotherapeutics Price Performance

ARTV opened at $3.16 on Thursday. Artiva Biotherapeutics has a 1 year low of $3.15 and a 1 year high of $17.31. The stock has a fifty day moving average price of $4.71 and a 200 day moving average price of $9.23.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ARTV. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics in the third quarter valued at approximately $42,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Artiva Biotherapeutics in the 4th quarter valued at $52,000. Wells Fargo & Company MN boosted its position in shares of Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after purchasing an additional 3,361 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of Artiva Biotherapeutics during the third quarter worth $135,000. Finally, JPMorgan Chase & Co. bought a new stake in Artiva Biotherapeutics in the third quarter valued at about $166,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.